Laboratoire français de Fractionnement et de Biotechnologies   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Les Ulis France (1994)

Organization Overview

First Clinical Trial
2004
NCT01349270
First Marketed Drug
2020
coagulation factor viia (recombinant) (NovoSevenRT)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Laboratoire français de Fractionnement et de Biotechnologies | Laboratoire Francais du Fractionnement et des Biotechnologies S.A.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 3)

Afibrinogenemia (Phase 3)

Amyotrophic Lateral Sclerosis (Phase 3)

Hemophilia A (Phase 3)

Hemophilia B (Phase 3)

Hemorrhage (Phase 4)

Leukemia (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Lymphoid (Phase 1)

Motor Neuron Disease (Phase 3)

Polyneuropathies (Phase 3)

Polyradiculoneuropathy (Phase 3)

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (Phase 3)

Postpartum Hemorrhage (Phase 4)

Respiratory Distress Syndrome (Phase 3)

Respiratory Distress Syndrome, Newborn (Phase 3)

Shock (Phase 4)

Shock, Septic (Phase 4)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 17
  • # of Trial APIs: 12